{"organizations": [], "uuid": "df6c652b30000581de4020bc3b5eecb8293e7952", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://feeds.reuters.com/reuters/companyNews", "section_title": "Reuters: Company News", "url": "https://www.reuters.com/article/brief-alimera-sciences-receives-acceptan/brief-alimera-sciences-receives-acceptance-of-filing-to-obtain-approval-for-iluvien-idUSFWN1OZ0MO", "country": "US", "domain_rank": 408, "title": "BRIEF-Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For Iluvien", "performance_score": 0, "site": "reuters.com", "participants_count": 0, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-04T14:33:00.000+02:00", "replies_count": 0, "uuid": "df6c652b30000581de4020bc3b5eecb8293e7952"}, "author": "", "url": "https://www.reuters.com/article/brief-alimera-sciences-receives-acceptan/brief-alimera-sciences-receives-acceptance-of-filing-to-obtain-approval-for-iluvien-idUSFWN1OZ0MO", "ord_in_thread": 0, "title": "BRIEF-Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For Iluvien", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "alimera sciences inc", "sentiment": "none"}, {"name": "obtain approval for iluvien reuters staff", "sentiment": "none"}, {"name": "reuters", "sentiment": "none"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "January 4, 2018 / 12:34 PM / Updated 9 minutes ago BRIEF-Alimera Sciences Receives Acceptance Of Filing To Obtain Approval For Iluvien Reuters Staff 1 Min Read \nJan 4 (Reuters) - Alimera Sciences Inc: \n* ALIMERA SCIENCES RECEIVES ACCEPTANCE OF FILING TO OBTAIN APPROVAL FOR ILUVIENÂ® NON-INFECTIOUS POSTERIOR UVEITIS INDICATION IN EUROPE Source text for Eikon: Further company coverage:", "external_links": [], "published": "2018-01-04T14:33:00.000+02:00", "crawled": "2018-01-04T14:47:18.036+02:00", "highlightTitle": ""}